Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kazansky, A. V.
Right arrow Articles by Rosen, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kazansky, A. V.
Right arrow Articles by Rosen, J. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 32, 22484-22492, August 6, 1999


Differential Effects of Prolactin and src/abl Kinases on the Nuclear Translocation of STAT5B and STAT5A*

Alexander V. Kazansky, Elena B. Kabotyanski, Shannon L. WyszomierskiDagger , Michael A. Mancini, and Jeffrey M. Rosen§

From the Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030-3498

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, DNA binding and tyrosine phosphorylation of STAT5A and STAT5B were compared with their subcellular localization determined using indirect immunofluorescence microscopy. Following prolactin activation, both STAT5A and STAT5B were rapidly translocated into the nucleus and displayed a detergent-resistant, punctate nuclear staining pattern. Similar to prolactin induction, src activation resulted in tyrosine phosphorylation and DNA binding of both STAT5A and STAT5B. However, nuclear translocation of only STAT5B but not STAT5A was observed. This selective nuclear translocation appears to be mediated via the carboxyl-terminal sequences in STAT5B. Furthermore, overexpression of a dominant negative kinase-inactive mutant of JAK2 prevented prolactin-induced tyrosine phosphorylation and nuclear translocation of STAT5A and STAT5B but did not block src kinase activation and nuclear translocation of STAT5B. In co-transfection assays, prolactin-mediated activation but not src kinase-mediated activation of STAT5B resulted in the induction of a beta -casein promoter-driven reporter construct. These results suggest that STAT5 activation by src may occur by a mechanism distinct from that employed in cytokine activation of the JAK/STAT pathway, resulting in the selective nuclear translocation of STAT5B.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cytokines influence a variety of cellular functions including proliferation, growth arrest, and differentiation. The neuroendocrine hormone prolactin (Prl)1 plays a central role in the development and differentiation of the mammary gland. Binding of Prl to its cell surface receptor, a member of the cytokine receptor superfamily, regulates the transcription of several milk protein genes, including the whey acidic protein (1), beta -lactoglobulin (2), and beta -casein (3, 4) genes. The Prl receptor (PrlR) transmits signals in part via activation of the JAK/signal transducers and activators of transcription (STAT) pathway. Interaction of Prl with PrlR induces receptor dimerization, activation of the JAK2 protein-tyrosine kinase (3, 5-7), and tyrosine phosphorylation of transcription factors that belong to the STAT family.

Among the seven mammalian STAT proteins that have been discovered (8), STAT1, STAT3, and STAT5 are capable of activation by the PrlR (9). STAT5, however, plays a key role in Prl-induced milk protein gene expression and mammary gland differentiation (10, 11). Tyrosine 700 of rat STAT5 is the site of phosphorylation by JAK2 and the primary regulator of STAT5 DNA binding (3). After tyrosine phosphorylation, STAT5 dimerizes and translocates into the nucleus, where it binds to specific DNA elements and activates transcription of target genes, such as the milk protein genes.

Two different STAT5 genes encoding STAT5A and STAT5B have been identified that share 93% identity at the amino acid level with the primary differences occurring at their carboxyl termini (12-14). STAT5A was discovered as a mediator of Prl response in mammary epithelial cells and was originally designated as mammary gland-specific factor, or MGF (4, 15). STAT5B was cloned from hematopoietic cells, mammary gland, and liver tissue (12, 14, 16, 17). STAT5A and STAT5B are ubiquitously expressed in most cell lines and tissues at comparable levels with a few exceptions (14).

In addition to Prl, both STAT5A and STAT5B are activated by many other cytokines, including growth hormone, erythropoietin, granulocyte-macrophage colony-stimulating factor (17, 18), IL-2 (19, 20), IL-3 (16, 17), IL-5 (17), IL-7, IL-15 (20), and thrombopoietin (21). STAT5 can also be activated by certain growth factors, like epidermal growth factor, through their respective receptor tyrosine kinases (22) as well as by certain nonreceptor tyrosine kinases like src and bcr-abl (23, 24). STAT5A and STAT5B can, therefore, participate in many different signaling pathways leading to cell growth and differentiation. The targeted knockout of the individual genes in mice has suggested that they play essential but often redundant roles in the physiological responses associated with Prl (25). Despite their homology, there is some evidence suggesting that STAT5A and STAT5B may be differentially activated (26) and even exhibit distinct DNA binding specificities (27). However, functional differences between STAT5A and STAT5B and their precise roles in normal mammary gland development and cancer are just beginning to be elucidated.

In this study, we have compared the kinetics of DNA binding and tyrosine phosphorylation of STAT5A and STAT5B following either Prl treatment or src/abl kinase activation with their subcellular localization determined by indirect immunofluorescence microscopy. src kinase activation resulted in tyrosine phosphorylation and DNA binding of both STAT5A and STAT5B, but unlike prolactin induction, nuclear translocation of only STAT5B but not STAT5A was observed. This selective nuclear translocation appears to be mediated via the carboxyl-terminal sequences in STAT5B and was not prevented but instead stimulated by a dominant-negative kinase-inactive mutant of JAK2. These observations establish another mechanism for STAT5 activation in response to the src/abl kinase family that results in the selective nuclear translocation of STAT5B and possibly activation of unique gene targets.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression and Reporter Constructs-- Rat STAT5A cDNA was cloned and characterized in our laboratory (13). Rat STAT5B was cloned by Guoyang Luo and Dr. Li-yuan Yu-Lee at Baylor College of Medicine (28). Both STAT5A and STAT5B were subcloned into the pRCCMV expression vector (Invitrogen, Carlsbad, CA). src kinase-active (srcK+) and dominant negative src (srcK-) constructs (29) were kindly provided by Dr. Sara Courtneidge at Sugen Corp. The JAK2 mutant expression vector (JAK829) has been described previously and was kindly provided by Dr. Nelson Horseman (30). A chimeric STAT5A:B expression construct was made by ligation of the 5' segment of STAT5A (HindIII/XhoI 1.7-kilobase fragment) to the 3' portion of STAT5B (XhoI/SpeI 0.9-kilobase fragment) in the HindIII/XbaI sites of the pCDNA3 vector. The -2300/+490 beta -casein gene promoter-CAT construct and the expression vector for the long form of PrlR have been described previously (31). All DNA plasmids were purified using a QIAGEN maxiprep kit (Qiagen, Valencia, CA).

Cell Culture and Transfections-- The majority of the experiments were performed using COS-1 cells maintained in Dulbecco's modified Eagle's medium (JRH, Lenexa, KS), which was supplemented with 10% fetal bovine serum (JRH), glutamine (2 mM), and gentamicin (50 µg/ml) in a 37 °C and 5% CO2 incubator. DNA constructs (10 µg) were transiently transfected into COS cells using LipofectAMINE reagent (Life Technologies, Inc.) at a working concentration of 5 µg/ml, according to the manufacturer's protocol. HeLa cells were grown in Opti-MEM media (Life Technologies), supplemented with 3% fetal bovine serum and gentamicin (50 µg/ml); transfections were performed by using a calcium phosphate precipitation technique (5 Prime right-arrow 3 Prime, Boulder, CO). For the co-transfection experiments, 2 µg of STAT5A or STAT5B expression vector, 3 µg of PrlR or src kinase constructs, and 5 µg of JAK829 expression vector were utilized. For the reporter gene assays, 4 µg of beta -casein promoter construct was used. Before Prl or src induction, the cells were switched overnight to medium containing 10% charcoal-stripped horse serum, insulin (5 µg/ml), gentamicin (50 µg/ml), and hydrocortisone (1 µg/ml) and then (for the Prl experiments only) stimulated with ovine Prl (1 µg/ml, lot; AFP-10677C kindly provided by the National Hormone and Pituitary Program, NIDDK, National Institutes of Health) as indicated. CAT assays were performed using a CAT enzyme-linked immunoassay kit (Roche Molecular Biochemicals) as specified by the manufacturer.

Preparation of Cell Extracts-- Cells were rinsed twice with ice-cold phosphate-buffered saline (Life Technologies) and scraped into radioimmunoprecipitation assay (RIPA) buffer (50 mM NaF, 10 mM Na4P2O7, 0.5% sodium deoxycholate, 0.1% SDS, 1% Nonidet P-40, 150 mM NaCl, 9.1 mM Na2HPO4, and 1.7 mM NaH2PO4, pH 7.4), containing protease and phosphatase inhibitors: 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, aprotinin (2 µg/ml), antipain (2 µg/ml), leupeptin (2 µg/ml), benzamidine (2 µg/ml). After incubation at 4 °C for 30 min, cell extracts were centrifuged, and supernatants were collected for Western blot analysis, immunoprecipitations, and electrophoretic mobility shift assays. Protein concentrations were measured using the Bio-Rad protein assay reagent (Bio-Rad).

Antibodies-- We have generated specific polyclonal antiserum in rabbits to the carboxyl-terminal region of STAT5A (13) and STAT5B (28) and to the activated forms that are phosphorylated on tyrosine 700 using the peptides indicated in Fig. 1. Antibodies were purified against corresponding antigenic peptides by affinity chromatography. For phosphotyrosine-specific antibodies, antisera were first purified by using an affinity column containing the nonphosphorylated peptide to remove antibodies that could react with nonphosphorylated forms. Antisera were then purified using an affinity column containing the phosphorylated peptide to enrich for fractions of the desired specificity. Enzyme-linked immunoassay and Western blot analyses were used to confirm that the resulting antibodies did not recognize nonphosphorylated forms of STAT5. NH2-terminal STAT5 (N-20) and c-abl antibodies were purchased from Santa Cruz Biotechnology. Anti-mouse monoclonal antibody to STAT5 and phosphotyrosine antibody (PY-20) were purchased from Transduction Laboratories (Lexington, KY). v-src antibody was purchased from Calbiochem.

Electrophoretic Mobility Shift Assays (EMSA), Immunoprecipitation, and Western Blot Analysis-- EMSA were performed as described previously (32). For immunoprecipitations, protein A-trysacryl (Pierce) was washed three times with RIPA buffer and diluted in RIPA buffer containing protease inhibitors in the volume twice the original volume. For each immunoprecipitation 400 µg of whole cell lysate was used. The cell extracts were first precleared by incubation with 40 µl of protein A-trysacryl for 15 min at 4 °C. After that, they were incubated with respective antibodies at a 1:100 dilution for 2 h at 4 °C, followed by incubation with protein A-trysacryl overnight at 4 °C. The immunoprecipitates were then collected by centrifugation, washed three times with RIPA, and dissociated by boiling in 2× denaturing buffer.

For Western blot analyses, we used 100 µg of total cell lysate per lane. Protein samples were separated by 7.5% SDS-polyacrylamide gel electrophoresis and transferred overnight to an Immunobilon-P membrane (Millipore Corp.). The membranes were blocked in 3% milk for 1 h at room temperature and incubated with primary antibody for 1 h at room temperature. They were then washed three times with TBS-T (20 mM Tris, pH 7.4, 150 mM NaCl, 0.05% Tween 20) and incubated with secondary antibody conjugated to horseradish peroxidase for 1 h at room temperature. After washing three times with TBS-T, the membranes were incubated for 30 min with streptavidin-horseradish peroxidase (1:2500 dilution) (Calbiochem), followed by five washes with TBS-T. Immunoreactive bands were visualized with Super Signal Chemiluminescent Substrate (Pierce). The primary antibodies, used for Western blot analysis were as follows: anti-Stat5a (COOH-terminal), diluted 1:1000; anti-Stat5b (COOH-terminal), diluted 1:2000; anti-Stat5YP (5A,5B:Y-700), diluted 1:500; and anti-phosphotyrosine (PY-20), diluted 1:1000.

Indirect Immunofluorescence-- Cells were cultured on glass coverslips, coated with poly-D-lysine (1 mg/ml, 70,000-150,000 Da; Sigma). After transfection, the cells were rinsed twice with ice-cold phosphate-buffered saline (Life Technologies) and then fixed with 4% paraformaldehyde in PEM buffer (80 mM PIPES, 1 mM EGTA, 1 mM MgCl2, pH 6.9) for 30 min. After washing coverslips three times with PEM buffer, they were incubated for 5 min in NaBH4 (1 mg/ml) solution in PEM buffer twice. Then they were washed with PEM twice and incubated with 0.5% Triton X-100 (Sigma) in the same buffer for 20 min. Alternatively, for extraction of soluble proteins that were not tightly associated with cellular structures such as the cytoskeleton and nuclear matrix (33), cells were permeabilized on ice before fixing for 3 min with 0.5% Triton X-100 in CSK buffer (10 mM PIPES, pH 6.8, 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, 300 mM sucrose), containing protease and RNase inhibitors: 1 mM phenylmethylsulfonyl fluoride, aprotinin (2 µg/ml), antipain (2 µg/ml), leupeptin (2 µg/ml), benzamidine (2 µg/ml), and vanadyl ribonucleaside complex (2 mM; 5 Prime right-arrow 3 Prime) (34). After fixing, coverslips were washed three times with PEM buffer and once with TBS-T (100 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween 20) and subjected to immunostaining.

For immunostaining, coverslips were blocked in 5% milk in TBS-T overnight at 4 °C and incubated with primary antibodies for 1 h at room temperature. After washing five times with TBS-T, cells were incubated with secondary antibodies conjugated with Texas Red (Molecular Probes, Inc., Eugene, OR) or fluorescein isothiocyanate (Santa Cruz Biotechnology) for 30 min in the dark at room temperature and then washed with TBS-T five times and stained by DAPI by using VECTASHIELD mounting media (VECTOR, Burlingame, CA). Images were obtained using a Zeiss Axiophot fluorescent microscope.

The primary antibodies used for immunostaining were as follows: anti-Stat5a (COOH-terminal), diluted 1:400; anti-Stat5b (COOH-terminal), diluted 1:500; anti-abl (c-abl) (Santa Cruz Biotechnology), diluted 1:400; and anti-src (v-src) (Calbiochem), diluted 1:250. For anti-Stat5a and anti-Stat5b antibodies, goat anti-rabbit IgG conjugated with Texas Red (1:1000) was used as the secondary antibody. Goat anti-mouse IgG conjugated with fluorescein isothiocyanate (1:500) was used as the secondary antibody for anti-abl and anti-src antibodies.

Analysis of STAT5 Nuclear Localization-- Two sets of coverslips were set up in the dish. One of them was pretreated with 0.5% Triton X-100 in CSK buffer in order to remove the soluble proteins from the cytoplasm and nuclei prior fixing the cells, while another set was fixed without pretreatment with Triton-CSK buffer. Both sets of coverslips were subjected to immunostaining. Nuclear staining was detected only in cells pretreated with Triton-CSK buffer, while the untreated cells exhibited both cytoplasmic and nuclear staining. The percentage of nuclear localization was measured by dividing the total number of cells stained for STAT5 following Triton-CSK pretreatment by the total number of cells exhibiting STAT5 staining without pretreatment relative to the average number of transfected cells. For each time point, 4-6 fields of view were analyzed.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Although there have been numerous studies following the kinetics of STAT tyrosine phosphorylation and DNA binding as a function of cytokine activation, there are relatively few reports in which the subcellular distribution of STATs following activation by either cytokines or nonreceptor tyrosine kinases such as src has been investigated. In fact, little is known about the mechanisms governing nuclear import and export of STATs. To perform these studies, it was necessary to generate highly specific, affinity-purified antisera raised against either the carboxyl termini of STAT5A and STAT5B proteins or to the phosphotyrosine 700 epitope (Fig. 1).


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 1.   Putative different functional domains in rat STAT5A and STAT5B and antibody epitopes. The COOH-terminal epitope used to generate the anti-Stat5a antibody, as indicated by the thin line, does not cross-react with STAT5B. Similarly, the COOH-terminal epitope used to generate the anti-Stat5b antibody, as indicated by the thick line, does not cross-react with STAT5A. The epitope for generating the anti-Stat5PY antibody that recognizes the specific peptide containing the phosphotyrosine required for STAT5 dimer formation and DNA binding is indicated by the double line.

Using these specific reagents, the tyrosine phosphorylation and DNA binding activity was initially compared with the nuclear localization of STAT5A and STAT5B following both Prl and src activation. Transfection experiments with cDNA expression plasmids encoding STAT5A or STAT5B and the PrlR were performed in COS-1 cells. For the src experiments, both constitutively active and dominant negative src kinase constructs were employed in similar transient transfection experiments but in the absence of the PrlR.

As illustrated in Fig. 2, Prl treatment as expected led to a rapid increase in tyrosine phosphorylation and DNA binding within 30 min for both STAT5A (Fig. 2, lane 2) and STAT5B (Fig. 2, lane 9). STAT 5A and STAT5B tyrosine phosphorylation was detected using both the specific STAT5A phosphotyrosine 700(YP) antibody by direct Western blotting and by the more conventional method of immunoprecipitating with anti-STAT5A or anti-STAT5B followed by Western blotting with a general anti-phosphotyrosine antibody. Prl induction of DNA binding activity of STAT5 has been shown previously to be accompanied by phosphorylation on Tyr700 (Tyr694 in sheep STAT5A (3)). The results illustrated in Fig. 2 suggest that Tyr700 is the primary epitope on STAT5 for PY-20 and indicate that the kinetics of total tyrosine phosphorylation of STAT5A and STAT5B parallel the phosphorylation of Tyr700. For both STAT5A and STAT5B, the maximal level of tyrosine phosphorylation was observed after 30 min of Prl exposure and then appeared to decrease with similar kinetics. Direct Western blot analysis with carboxyl-terminal antibodies revealed that the total expression level of STAT proteins was relatively uniform in the transiently transfected COS-1 cells (Fig. 2, second panel). However, in the case of STAT5B, the appearance of slower mobility hyperphosphorylated forms that can be resolved from the nonphosphorylated forms by 7.5% SDS-polyacrylamide gel electrophoresis was observed to parallel the changes in tyrosine phosphorylation.


View larger version (52K):
[in this window]
[in a new window]
  		Fig. 2.   Kinetics of tyrosine phosphorylation and DNA binding activity of STAT5A and STAT5B in response to Prl induction and src kinase activation. COS cells were transiently co-transfected with STAT5A (lanes 1-7) or STAT5B (lanes 8-14) and PrlR (lanes 1-5 and 8-12), constitutively active src kinase (lanes 7 and 14), or a dominant negative src kinase (lanes 6 and 11), and in the lanes indicated they were induced by Prl for the times shown. Whole cell lysates were analyzed. The top two panels show direct Western blots with the antibodies listed. In the second panel, the slower mobility form of STAT5B is the most highly phosphorylated, while the faster mobility form is nonphosphorylated (lanes 8-12). In the third panel, samples were first immunoprecipitated (IP) with the antibody listed and then probed with the anti-phosphotyrosine antibody PY-20. The bottom panel shows an EMSA using a double-stranded oligonucleotide corresponding to a 34-base pair region of the beta -casein proximal promoter containing the STAT5 binding site.

To establish the time course of DNA binding activity for STAT5A and STAT5B, EMSAs were performed using whole cell extracts and a double-stranded oligonucleotide corresponding to a 34-base pair region of the beta -casein proximal promoter containing the STAT5 binding site (Fig. 2, bottom panel, lanes 1-5 and lanes 8-12, respectively). Similar to the tyrosine phosphorylation results, STAT5A and STAT5B DNA binding activity reached a maximum after 30 min of Prl induction and subsequently decreased at longer times of Prl treatment. As expected, the phosphorylation status of STAT5A and STAT5B in response to Prl induction generally correlated with their DNA binding activity

Tyrosine phosphorylation and DNA binding activity of STAT5A and STAT5B were also increased by a constitutively active src (srcK+, Fig. 2, lanes 7 and 14) but were not observed following transfection of a src kinase, dominant negative (srcK-, Fig. 2, lanes 6 and 7) construct. Direct Western blot analysis revealed phosphorylation of both STAT5A and STAT5B (Fig. 2, top two panels, lanes 7 and 14) on Tyr700 as a result of co-transfection of srcK+. Similar results were obtained from immunoprecipitation experiments for STAT5A and STAT5B (Fig. 2, third panel, lanes 7 and 14). The DNA binding activity of STAT5A and STAT5B in response to src kinase activation was also demonstrated by EMSA (Fig. 2, bottom panel, lanes 7 and 14). No significant differences in the phosphorylation status or DNA binding activity in response to src were detected between STAT5A and STAT5B using these techniques.

Cytoplasmic-Nuclear Transport of STAT5A and STAT5B in Response to Prl Induction-- Using indirect immunofluorescence, it was possible to examine if the decrease in STAT5A and STAT5B tyrosine phosphorylation and DNA binding activity (Fig. 2) with time after Prl treatment was correlated with the changes in subcellular localization of these transcription factors. In cells transfected with PrlR and STAT5A or STAT5B without Prl treatment, both STAT5A and STAT5B appear to be predominantly localized in the cytoplasm (Fig. 3, A and B, respectively). Using deconvolution confocal microscropy, some staining for both STAT5A and STAT5B could be detected in the nucleus in the absence of prolactin activation (data not shown). Similar observations using GFP-STAT5B constructs and confocal microscropy have been reported recently in human fibrosarcoma cells (35). However, the nuclear staining observed in the absence of Prl in our studies was completely removed by extraction with O.5% Triton in CSK buffer, suggesting a loose association of nonactivated STAT5A and STAT5B in the nucleus. After 30 min of Prl stimulation, both STAT5A and STAT5B translocate into the nucleus and generate detergent-resistant complexes (Fig. 3, C and D, respectively). For both STAT5A and STAT5B, a specific punctate pattern of nuclear staining was observed that was resistant to Triton-CSK extraction.


View larger version (68K):
[in this window]
[in a new window]
  		Fig. 3.   STAT5A and STAT5B localization in response to Prl and src kinase activation. COS cells were transiently co-transfected with STAT5A (A, C, and E) or STAT5B (B, D, and F) and PrlR (A-D) or the constitutively active src kinase (E and F) and induced by Prl for 30 min (C and D). Immunofluorescence analysis was performed using anti-Stat5a (A, C, and E) and anti-Stat5b (B, D, and F) antibodies. Red, anti-rabbit STAT5A or STAT5B, respectively; blue, nuclear staining with DAPI.

Differential Localization of STAT5A and STAT5B in Response to src/abl Kinase Activation-- Tyrosine phosphorylation and DNA binding of STAT5A and STAT5B appear similar in response to Prl and srcK+ activation (Fig. 2). Thus, it was expected that STAT5A and STAT5B would also exhibit similar nuclear translocation in response to SrcK+ activation. However, surprisingly when transiently transfected COS cells co-expressing srcK+ and STAT5A or STAT5B were examined by indirect immunofluorescent microscopy, it was discovered that only STAT5B was localized in the nucleus following src activation. STAT5A remained in the cytoplasm (Fig. 3, compare E (for STAT5A) and F (for STAT5B)). This was confirmed in experiments using double immunofluorescence staining in which STAT5A or STAT5B was localized using specific carboxyl-terminal antibodies with corresponding secondary antibodies conjugated with Texas Red and srcK+ was localized with an anti-v-src antibody recognized with a corresponding secondary antibody conjugated with fluorescein isothiocyanate. In cells co-transfected with cDNA encoding STAT5A and srcK+, predominantly yellow cytoplasmic staining formed by the combination of the green and red fluorescence was observed (Fig. 4A). In contrast, in cells co-expressing STAT5B and srcK+, green cytoplasmic staining for src and punctated red nuclear staining for STAT5B was observed (Fig. 4B). The punctate nuclear pattern observed following src activation was similar to that seen for STAT5B after stimulation with Prl. Furthermore, a similar pattern of selective nuclear translocation for STAT5B activated by c-abl, another member of the same nonreceptor tyrosine kinase family was also detected (Fig. 4C).


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4.   Nuclear translocation of STAT5A and STAT5B in response to src and abl kinase activation. Immunofluorescence analysis after co-transfection of COS cells with STAT5A (A) or STAT5B (B) and srcK+. Red, anti-rabbit Stat5a or Stat5b antibody, respectively; green, anti-mouse v-src antibody; blue, nucleus staining by DAPI. C, immunofluorescence analysis after co-transfection of STAT5B and c-abl. Red, anti-rabbit Stat5b antibody; green, anti-mouse c-abl antibody; blue, nucleus staining by DAPI.

Identification of the Sequences Required for the Selective Nuclear Translocation of STAT5B in Response to src Activation-- Because the sequence differences between the two isoforms of STAT5 are most pronounced in the carboxyl terminus, we constructed a chimeric STAT5A:B mutant, that consisted of 545 amino acids from the NH2-terminal end of STAT5A and 241 amino acids from the COOH-terminal end of STAT5B. Based upon the structural analysis of the STAT proteins, the STAT5A/B chimeric construct was made in the linker domain between the DNA binding and Src homology 2 domains of STAT5A and STAT5B (36) and presumably does not affect the ability of STAT5 to dimerize or form tetramers on the appropriate DNA response elements (37). This chimera was co-transfected in HeLa cells with the PrlR or srcK+. In parallel, STAT5A and STAT5B were expressed with the PrlR or srcK+ as positive and negative controls. The control experiments showed similar patterns for STAT5A (data not shown) and STAT5B localization in HeLa cells (Fig. 5, A-C) as observed previously in COS cells, confirming that the localization patterns did not result from marked overexpression of these proteins in COS cells. Remarkably, the chimeric STAT5A:B mutant translocated to the nucleus in response to both Prl induction and srcK+ activation (Fig. 5, E and F, respectively). This result suggests that STAT5B contains a unique sequence in its carboxyl terminus that could be responsible for nuclear translocation in response to src activation.


View larger version (45K):
[in this window]
[in a new window]
  		Fig. 5.   Nuclear translocation of STAT5B and chimeric STAT5A:B in response to Prl induction and src activation in HeLa cells. HeLa cells were transfected with STAT5B (A, B, and C) or STAT5A:B chimera (D, E, and F); STAT5B and STAT5A:B chimera were co-transfected with PrlR and treated with Prl for 30 min (B and E); STAT5B and STAT5A:B were co-transfected with constitutively active src kinase (C and F). A and D, no Prl treatment. Immunofluorescence analysis was performed using anti-Stat5b and v-src antibodies. Red, anti-rabbit Stat5b antibody; green, anti-mouse v-src antibody; blue, nuclear staining by DAPI.

Association of STAT5 with src Kinase and the Role of JAK2 in Nuclear Translocation-- Although src has been shown to associate with and phosphorylate STAT3 both in vivo and in vitro (38) it was unclear whether src could associate with and phosphorylate either STAT5A or STAT5B. Accordingly, immunoprecipitation with an anti-src antibody followed by Western blotting with an antibody that will recognize either STAT5A or STAT5B was performed using extracts prepared from transiently transfected COS cells. These experiments demonstrated that src kinase is capable of in vivo association with both STAT5A and STAT5B (Fig. 6). However, this association appeared not to be dependent upon the enzymatic activity of src kinase, since it was observed in both srcK+ and srcK- cells. Furthermore, in vitro kinase assays failed to reveal an increase in STAT5A or STAT5B tyrosine phosphorylation (data not shown) in the co-immunoprecipitated complex, suggesting that this was not a direct kinase-substrate interaction.


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 6.   Co-immunoprecipitation of STAT5 isoforms with src kinase. Lysates of COS cells co-transfected with STAT5A (lanes 1-3) or STAT5B (lanes 4-6) with constitutively active src kinase (lanes 3 and 6) or dominant negative src kinase (lanes 2 and 5) were immunoprecipitated with an anti-v-src antibody. Cells transfected with constitutively active src kinase alone (lane 7) and nontransfected cells (lane 8) were immunoprecipitated as controls. The immunoprecipitated proteins were subjected to Western blot analysis using the anti-Stat5 monoclonal antibody.

Having determined that the activation of both STAT5A and STAT5B by src kinase is not a direct enzyme-substrate reaction, we wished to investigate whether srcK+ might activate either STAT5 indirectly through the activation of JAK2. For this purpose, a dominant negative mutant of JAK2 consisting of a carboxyl-terminal truncation deleting the entire kinase domain (JAK829) (30) was utilized. STAT5A or STAT5B and PrlR or srcK+ were co-transfected in COS cells with or without JAK829. Whole cell extracts were prepared for immunoprecipitation, Western blotting, and immunofluorescent analyses (Fig. 7). As expected (39), overexpression of the kinase-inactive, dominant negative mutant of JAK2 blocked Prl-inducible tyrosine phosphorylation of STAT5A and STAT5B (Fig. 7, A and B, lanes 1-3). However, the JAK2 dominant negative mutant did inhibit block src-inducible tyrosine phosphorylation of STAT5A (Fig. 7A, lanes 4 and 5) or STAT5B (Fig. 7B, lanes 4 and 5). Immunofluorescence analyses were consistent with these results. In cells co-transfected with STAT5A or STAT5B, PrlR, and JAK829 and treated with Prl for 30 min, exclusive cytoplasmic staining for both STAT5s was observed, similar to cells that did not receive Prl treatment (data not shown). In cells co-expressing STAT5B, srcK+, and JAK829, punctated nuclear staining similar to that seen in cells without JAK829 was observed (data not shown). The analysis of numerous fields was performed in order to calculate the percentage of cells displaying nuclear localization (Fig. 8). These results indicate that JAK829 significantly reduced the nuclear translocation of STAT5B induced by Prl, but not by src kinase. In contrast, in cells co-expressing STAT5B and srcK+, an increased level of tyrosine phosphorylation and nuclear localization of STAT5B was detected in the presence of JAK829 compared with cells not expressing the dominant-negative JAK2 mutant. These results suggest that src activation of STAT5B may occur by a mechanism independent of the conventional ligand-dependent activation of the JAK/STAT pathway (Fig. 10 and "Discussion").


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 7.   Phosphorylation of STAT5A and STAT5B by src kinase is not inhibited by a dominant-negative mutant of JAK2. COS cells were co-transfected with STAT5A (A) or STAT5B (B) and PrlR (lanes 1-3), constitutively active src kinase (lanes 4 and 5), and the dominant negative JAK2 mutant (lanes 3 and 5) and induced by Prl for 30 min as indicated (lanes 2 and 3). STAT5 was immunoprecipitated with an NH2-terminal anti-Stat5 antibody. The immunoprecipitated proteins were subjected to Western blot analysis using the PY-20 anti-phosphotyrosine antibody. The blots were then stripped and probed with the anti-Stat5 monoclonal antibody.


View larger version (8K):
[in this window]
[in a new window]
  		Fig. 8.   Nuclear translocation of STAT5B by src kinase is not prevented by a dominant negative JAK2 mutant. Quantitative analysis of nuclear localization of STAT5B performed by immunofluorescence staining of co-transfected COS cells as described under "Experimental Procedures."

STAT5B Does Not Activate Transcription from the beta -Casein Gene Promoter after src Kinase-mediated Nuclear Translocation-- Since both Prl and srcK+ activation result in STAT5B tyrosine phosphorylation, nuclear translocation, and DNA binding, it was reasonable to examine if these pathways are transcriptionally equivalent. beta -Casein is a well characterized STAT5 target gene. Prl induces beta -casein gene expression through STAT5A and STAT5B both in mammary epithelial cells (15, 40) and in COS cells (3) and CHO cells (4). STAT5A and STAT5B bind to the region between -105 and -75 in the beta -casein gene promoter (40, 41), which contains the recognition site for STAT5, a highly conserved sequence 5'-CTTCTTGGAATT-3'. A beta -casein gene promoter fragment (-2300/+490) linked to the CAT gene as a reporter was transfected into COS cells with the PrlR or srcK+ expression vectors. Cellular extracts were prepared, and CAT activity was determined. In cells transfected with the promoter-reporter gene construct, STAT5B, and PrlR and treated with Prl overnight, an expected 4.5-fold increase (3) in CAT protein was detected as compared with cells treated with only insulin and glucocorticoids (Fig. 9). However, STAT5B co-expressed with srcK+ was unable to cause transactivation of the beta -casein gene promoter (Fig. 9). Western blot and indirect immunofluorescent analyses of STAT5B were performed in parallel to these transactivation experiments to demonstrate src activation of STAT5B tyrosine phosphorylation and nuclear translocation (data not shown). These results suggest that src activation is not transcriptionally equivalent to Prl activation.


View larger version (9K):
[in this window]
[in a new window]
  		Fig. 9.   Src-activated STAT5B does not activate a beta -casein promoter-driven reporter construct. COS cells were co-transfected with a beta -casein CAT construct, STAT5B and with constitutively active src kinase or with PrlR without or with induction by Prl for 24 h. CAT concentrations were determined by an enzyme-linked immunoassay assay.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Differential Effects of src/abl Kinases on the Nuclear Localization of STAT5A and STAT5B-- The general paradigm for JAK/STAT signaling is that ligand binding to cytokine receptors leads to JAK kinase activation and STAT tyrosine phosphorylation, followed by dimerization and obligatory nuclear translocation. However, as reported in this study, signals from the src/abl family of protein kinases also led to STAT5 activation but did not result in the equivalent nuclear translocation of STAT5A and STAT5B. This appears to represent a novel property of cytokine-independent pathways for STAT activation (Fig. 10). Furthermore, recent observations suggest that there are distinct biochemical differences between the closely related STAT5A and STAT5B proteins (37) that could potentially result in the differential activation of STAT5 gene targets (27). Thus, the preferential nuclear translocation of STAT5B as well as other STAT proteins provides another level of gene regulation that may have profound biological consequences. These studies also illustrate the importance of analyzing the subcellular distribution of STAT proteins following activation in addition to merely assessing their tyrosine phosphorylation and in vitro DNA binding activity by EMSA. For example, discrepancies between cell fractionation and immunofluorescence results have been reported when analyzing the nuclear translocation of STAT chimeras (42).


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 10.   STAT5 activation mechanisms. A, cytokine-dependent pathway. Binding of Prl to its membrane receptor activates the tyrosine kinase JAK2. This kinase catalyzes the tyrosine phosphorylation of STAT5A and STAT5B. After tyrosine phosphorylation, STAT5 isoforms form homo- or heterodimers, which translocate into the nucleus, where they bind to specific DNA response elements and activate transcription of target genes presumably facilitating the proliferation and terminal differentiation of mammary epithelial cells. B, cytokine-independent pathway. STAT5B is activated by src kinase via an indirect mechanism. After tyrosine phosphorylation, STAT5B homodimers translocate into the nucleus, where they may facilitate the selective regulation of genes involved in proliferation and/or apoptosis.

Little is known about the mechanisms regulating the nuclear import and export of STAT proteins. STAT1 nuclear import following activation by interferon-gamma is mediated by a Ran GTPase-dependent process involving a nuclear pore-targeting complex with NPI-1 (43, 44). However, no conventional nuclear localization signals have been identified in the STAT proteins. In fact, it has been hypothesized that a ligand-receptor complex might function as a chaperone to facilitate STAT nuclear import (45, 46). Such a mechanism appears unlikely to account for the selective nuclear import of STAT5B by the src/abl kinases.

While little is known about the mechanisms of nuclear import, even less is known about the mechanisms regulating nuclear export of STATs. Limited studies have suggested that nuclear export appears to be dependent upon a nuclear tyrosine phosphatase (47). Pulse-chase studies have indicated that STAT1 cycles into the nucleus as tyrosine-phosphorylated molecules and quantitatively returns to the cytoplasm as nonphosphorylated molecules (47).

Although STAT5A and STAT5B display 93% identity at the amino acid level, the chimeric construct in which the amino-terminal region of STAT5A was fused to the carboxyl terminus of STAT5B still exhibited src kinase-dependent nuclear translocation, and, as expected, responded to Prl activation (Fig. 5). Recent analysis of STAT chimeras has suggested that STAT amino termini provide a signal that is important for nuclear translocation and subsequently deactivation (42). However, the analysis of STAT5A/5B chimeras in our study suggests that differences at the amino termini cannot account for the selective effects of src on the nuclear import of STAT5B as compared with STAT5A. There are two regions in the carboxyl-terminal regions of STAT5A and STAT5B that display significant differences (Fig. 1). The principal difference between these two STATs is at the carboxyl terminus in a region thought to be a transcriptional transactivation domain (48). In addition, there is a six-amino acid difference in STAT5B immediately amino-terminal to tyrosine 700. We thought that the sequence, PCEPAT, might be important for the selective effects on STAT5B nuclear localization and generated the respective in frame deletion in STAT5B. Preliminary results indicate that this deletion did not inhibit src-dependent nuclear translocation (data not shown). More detailed analysis of carboxy-deleted naturally occurring splice variants of STAT5B (14) and additional chimeric constructs may be informative for the identification of the precise determinants that discriminate between the selective nuclear localization of STAT5A and STAT5B.

Biological Consequences of STAT5B Activation-- The src family of protein-tyrosine kinases are involved in signal transduction pathways that result in growth and differentiation (49, 50) and when dysregulated can result in a variety of pathological conditions including cancer (51-53). A number of primary tumors and tumor-derived cell lines including breast and colon cancer, melanoma, and sarcoma have been shown to possess elevated src tyrosine kinase activity (54-57). src and its family members are required for mitogenesis initiated by several growth factor receptors, including epidermal growth factor receptor (58-60), platelet-derived growth factor receptor (50, 61-63), basic fibroblast growth factor receptor (64, 65), and colony-stimulating factor-1 receptor (49, 60). A number of different substrates have been identified for src kinase including contractin (66-68), p125FAK (69), and p130cas (70), but how src contributes to the mitogenic response is still not well understood.

It has been demonstrated that in addition to their signaling functions in normal cells, STATs can also participate in oncogenesis (71). A number of reports correlate STAT activation with the activity of nonreceptor proto-oncogenic tyrosine kinases such as v-src (38, 72, 73), v-abl (74), lyn (75), lsk (76), bcr/abl (77), and fes (78). Thus, constitutive, non-cytokine activation of STATs may play an important role in the etiology of primary lymphoid and myeloid leukemias as well as in breast cancer (24, 72, 79). In support of this hypothesis, recent functional studies have demonstrated that STAT3 activation is required for transformation of mammalian fibroblasts (80). A reciprocal pattern of STAT5 and STAT3 activation has been observed during mammary gland development (10), suggesting that these STAT proteins may play different or even opposite roles in the regulation of cell proliferation, differentiation, and apoptosis (10). Conceivably, src activation may disrupt these processes.

Although it has been reported that src-transformed cells exhibit constitutive activation of JAK1 and possibly JAK2 (81), there is some evidence that v-src and bcr/abl may, in addition, be directly associated with STATs (23, 24). This is consistent with the observation that dominant negative mutant of JAK2 did not prevent STAT5B activation by src (Fig. 7). In fact, in the presence of the dominant negative JAK2 mutant, increased STAT5B nuclear translocation was observed (Fig. 8). Thus, it is conceivable that JAK2 and src might compete for activation of STAT5B, and expression of the dominant negative JAK2, therefore, resulted in a small increase in src activation of STAT5B. Interestingly, a dominant negative JAK2 has also been reported not to prevent IL-3-mediated activation of STAT3, which is thought to be mediated in part by c-src (82).

Our results provide evidence that the interaction of the src kinase with STAT5 is most likely not a kinase-substrate interaction and that activation of STAT5B occurs through an undetermined indirect mechanism. The interaction of src and STAT5 observed in the co-immunoprecipitation/Western blotting experiments is most likely due to direct or indirect interaction with its Src homology 2 domains. It is possible that STAT5B is a target of tyrosine kinases activated by src and/or that src may serve as an adaptor protein facilitating STAT5B association as part of a multiprotein complex. For example, src kinase has been shown to bind to and phosphorylate the adapter protein p130cas, an important modulator of signal transduction.

In addition to the JAK/STAT pathway, PrlR signaling may be mediated via the MAP kinase pathway and by activation of members of the src kinase family (83-85). However, despite these observations, the activation of STAT5B by src failed to activate a beta -casein-CAT reporter construct that contains a consensus mammary gland-specific factor-binding site for STAT5 (Fig. 9). Prl activation of STAT5B has been reported to be sufficient for the activation of beta -casein promoter-driven reporter constructs in COS cells (12). The beta -casein gene promoter, however, contains binding sites for a number of other transcription factors that comprise a composite response element responsible for both lactogenic hormone and developmental regulation (86). Thus, it is conceivable that src kinase influences either directly or indirectly the activity of these other factors, leading to the inhibition of casein gene expression independently of activated STAT5B. A similar inhibition of lactogenic hormone signaling by other proto-oncogenes has been reported (87).

In conclusion, these studies have suggested that ligand-dependent and -independent signaling pathways may differentially regulate STAT5A and STAT5B nuclear translocation. One potential consequence may be the differential activation of gene targets involved in differentiation, proliferation, or apoptosis.

    ACKNOWLEDGEMENTS

We thank Maureen G. Mancini for invaluable assistance and advice concerning the indirect immunofluorescence microscopy analyses, Dr. Li-yuan Yu-Lee for a critical reading of the manuscript, and Alvenia Daniels for superb secretarial assistance.

    FOOTNOTES

* These studies were supported by NCI, National Institutes of Health, Public Health Service Grant CA16303.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by Department of Defense Breast Cancer Training Grant DAMD 17-94-J-4204.

§ To whom correspondence should be addressed. Tel.: 713-798-6210; Fax: 713-798-8012; E-mail: jrosen@bcm.tmc.edu.

    ABBREVIATIONS

The abbreviations used are: Prl, prolactin; PrlR, Prl receptor; STAT, signal transducers and activators of transcription; IL, interleukin; CAT, chloramphenicol acetyltransferase; PIPES, 1,4-piperazinediethanesulfonic acid; DAPI, 4',6-diamidino-2-phenylindole; RIPA, radio immunoprecipitation assay.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Li, S., and Rosen, J. (1995) Mol. Cell. Biol. 15, 2063-2070[Abstract]
2. Burdon, T. G., M. K. A., Clark, A. J., Wallace, R., and Watson, C. J. (1994) Mol. Endocrinol. 8, 1528-1536[Abstract/Free Full Text]
3. Gouilleux, F., Wakao, H., Mundt, M., and Groner, B. (1994) EMBO J. 13, 4361-4368[Medline] [Order article via Infotrieve]
4. Wakao, H., Gouilleux, F., and Groner, B. (1994) EMBO J. 13, 2182-2191[Medline] [Order article via Infotrieve]
5. Campbell, G., Argetsinger, L., Ihle, J., Kelly, P., Rillema, J., and Garter-Su, C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5232-5236[Abstract/Free Full Text]
6. Rui, H., Kirken, R. A., and Farrar, W. L. (1994) J. Biol. Chem. 269, 5364-5368[Abstract/Free Full Text]
7. Dusanter-Fourt, I., Muller, O., Ziemiecki, A., Mayeux, P., Drucker, B., Djiane, J., Wilks, A., Harpur, A. G., Fischer, S., and Gisselbrecht, S. (1994) EMBO J. 13, 2583-2591[Medline] [Order article via Infotrieve]
8. Darnell, J. E., Jr. (1997) Science 277, 1630-1635[Abstract/Free Full Text]
9. DaSilva, L., Rui, H., Erwin, R. A., Howard, O. M., Kirken, R. A., Malabarba, M. G., Hackett, R. H., Larner, A. C., and Farrar, W. L. (1996) Mol. Cell. Endocrinol. 117, 131-140[CrossRef][Medline] [Order article via Infotrieve]
10. Liu, X., Robinson, G., and Hennighausen, L. (1996) Mol. Endocrinol. 10, 1496-1506[Abstract/Free Full Text]
11. Liu, X., Robinson, G., Wagner, K., Garrett, L., Wynshaw-Boris, A., and Hennighausen, L. (1997) Genes Dev. 11, 179-186[Abstract/Free Full Text]
12. Liu, X., Robinson, G. W., Gouilleux, F., Groner, B., and Hennighausen, L. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8831-8835[Abstract/Free Full Text]
13. Kazansky, A., Raught, B., Lindsey, S., and Wang, Y. (1995) Mol. Endocrinol. 9, 1598-1609[Abstract/Free Full Text]
14. Ripperger, J. A., Fritz, S., Richter, K., Hocke, G. M., Lottspeich, F., and Fey, G. H. (1995) J. Biol. Chem. 270, 29998-30006[Abstract/Free Full Text]
15. Schmitt-Ney, M., Doppler, W., Ball, R., and Groner, B. (1991) Mol. Cell. Biol. 11, 3745-3755[Abstract/Free Full Text]
16. Azam, M., Erdjument-Bromage, H., Kreider, B., Xia, M., Quelle, F., Basu, R., Saris, C., Tempst, P., Ihle, J., and Schindler, C. (1995) EMBO J. 14, 1402-1411[Medline] [Order article via Infotrieve]
17. Mui, A.-F., Wakao, H., O'Farrel, A., Harada, N., and Miyajima, A. (1995) EMBO J. 14, 1166-1176[Medline] [Order article via Infotrieve]
18. Gouilleux, F., Pallard, C., Dusanter-Fourt, I., Wakao, H., Haldosen, L.-A., Norstedt, G., Levy, D., and Groner, B. (1995) EMBO J. 14, 2005-2013[Medline] [Order article via Infotrieve]
19. Gouilleux, F., Moritz, D., Humar, M., Moriggl, R., Berchtold, S., and Groner, B. (1995) Endocrinology 136, 5700-5708[Abstract]
20. Lin, J., Migone, T., Tsang, M., Friedmann, M., Wheatherbee, J., Zhon, L., Yamauchi, A., Bloom, E., Mietz, J., John, S., and Leonard, W. (1995) Immunity 2, 331-339[CrossRef][Medline] [Order article via Infotrieve]
21. Pallard, C., Gouilleux, F., Benit, L., Cocault, L., Souyri, M., Levy, D., Groner, B., Gisselbrecht, S., and Dusanter-Fourt, I. (1995) EMBO J. 14, 2847-2856[Medline] [Order article via Infotrieve]
22. Ruff-Jamison, S., Chen, K., and Cohen, S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4215-4218[Abstract/Free Full Text]
23. Frank, D., and Varticovski, L. (1996) Leukemia 10, 1724-1730[Medline] [Order article via Infotrieve]
24. Ilaria, R., and van Ettens, R. (1996) J. Biol. Chem. 271, 31704-31710[Abstract/Free Full Text]
25. Teglund, S., McKay, C., Schuetz, E., van Deursen, J. M., Stravopodis, D., Wang, D., Brown, M., Bodner, S., Grosfeld, G., and Ihle, J. N. (1998) Cell 93, 841-850[CrossRef][Medline] [Order article via Infotrieve]
26. Meinke, A., Barahmand-Pour, F., Wohrl, S., Stoiber, D., and Decker, T. (1996) Mol. Cell. Biol. 16, 6937-6944[Abstract]
27. Boucheron, C., Dumon, S., Santos, S. C., Moriggl, R., Hennighausen, L., Gisselbrecht, S., and Gouilleux, F. (1998) J. Biol. Chem. 273, 33936-33941[Abstract/Free Full Text]
28. Luo, G., and Yu-Lee, L. (1997) J. Biol. Chem. 272, 26841-26849[Abstract/Free Full Text]
29. Twamley-Stein, G., Pepperkok, R., Ansorge, W., and Courtneidge, S. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7696-7700[Abstract/Free Full Text]
30. Zhuang, H., Patel, S. V., He, T. C., Sonsteby, S. K., Niu, Z., and Wojchowski, D. M. (1994) J. Biol. Chem. 269, 21411-21414[Abstract/Free Full Text]
31. Ali, S., Edery, M., Pellegrini, I., Lesueur, L., Paly, J., Djiane, J., and Kelly, P. (1992) Mol. Endocrinol. 6, 1242-1248[Abstract/Free Full Text]
32. Raught, B., Khursheed, B., Kazansky, A., and Rosen, J. (1994) Mol. Cell. Biol. 14, 1752-1763[Abstract/Free Full Text]
33. Belkin, A. M., and Burridge, K. (1995) Exp. Cell Res. 221, 132-140[CrossRef][Medline] [Order article via Infotrieve]
34. Capco, D. G., Wan, K. M., and Penman, S. (1982) Cell 29, 847-858[CrossRef][Medline] [Order article via Infotrieve]
35. Herrington, J., Rui, L., Luo, G., Yu-, Lee, L. Y., and Carter-Su, C. (1999) J. Biol. Chem. 274, 5138-5145[Abstract/Free Full Text]
36. Becker, S., Groner, B., and Muller, C. W. (1998) Nature 394, 145-151[CrossRef][Medline] [Order article via Infotrieve]
37. Verdier, F., Rabionet, R., Gouilleux, F., Beisenherz-Huss, C., Varlet, P., Muller, O., Mayeux, P., Lacombe, C., Gisselbrecht, S., and Chretien, S. (1998) Mol. Cell. Biol. 18, 5852-5860[Abstract/Free Full Text]
38. Cao, X., Tay, A., Guy, G., and Tan, Y. (1996) Mol. Cell. Biol. 16, 1595-1603[Abstract]
39. Han, Y., Doppler, W., Rogers, N. C., and Stark, G. R. (1997) Mol. Endocrinol. 11, 1180-1188[Abstract/Free Full Text]
40. Schmitt-Ney, M., Happ, B., and Ball, R. K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3130-3134[Abstract/Free Full Text]
41. Doppler, W., Groner, B., and Ball, R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 104-108[Abstract/Free Full Text]
42. Strehlow, I., and Schindler, C. (1998) J. Biol. Chem. 273, 28049-28056[Abstract/Free Full Text]
43. Sekimoto, T., Nakajima, K., Tachibana, T., Hirano, T., and Yoneda, Y. (1996) J. Biol. Chem. 271, 31017-31020[Abstract/Free Full Text]
44. Sekimoto, T., Imamoto, N., Nakajima, K., Hirano, T., and Yoneda, Y. (1997) EMBO J. 16, 7067-7077[CrossRef][Medline] [Order article via Infotrieve]
45. Johnson, H. M., Torres, B. A., Green, M. M., Szente, B. E., Siler, K. I., Larkin, J., III, and Subramaniam, P. S. (1998) Biochem. Biophys. Res. Commun. 244, 607-614[CrossRef][Medline] [Order article via Infotrieve]
46. Johnson, H. M., Torres, B. A., Green, M. M., Szente, B. E., Siler, K. I., Larkin, J., III, and Subramaniam, P. S. (1998) Proc. Soc. Exp. Biol. Med. 218, 149-155[CrossRef][Medline] [Order article via Infotrieve]
47. Haspel, R. L., Salditt-Georgieff, M., and Darnell, J. E., Jr. (1996) EMBO J. 15, 6262-6268[Medline] [Order article via Infotrieve]
48. Moriggl, R., Gouilleux-Gruart, V., Jahne, R., Berchtold, S., Gartmann, C., Liu, X., Hennighausen, L., Sotiropoulos, A., Groner, B., and Gouilleux, F. (1996) Mol. Cell. Biol. 16, 5691-5700[Abstract]
49. Courtneidge, S., Dhand, R., Pilat, D., Twamley, G., Waterfield, M., and Roussel, M. (1993) EMBO J. 12, 943-950[Medline] [Order article via Infotrieve]
50. Kypta, R., Goldberg, Y., Ulug, E., and Courtneidge, S. (1990) Cell 62, 481-492[CrossRef][Medline] [Order article via Infotrieve]
51. Erpel, T., and Courtneidge, S. (1995) Curr. Opin. Cell Biol. 7, 176-182[CrossRef][Medline] [Order article via Infotrieve]
52. Ihle, J. (1995) Nature 377, 591-594[CrossRef][Medline] [Order article via Infotrieve]
53. Pendergast, A. (1996) Curr. Opin. Cell Biol. 8, 174-181[CrossRef][Medline] [Order article via Infotrieve]
54. Rosen, N., Bolen, J. B., Schwartz, A. M., Cohen, P., DeSeau, V., and Israel, M. A. (1986) J. Biol. Chem. 261, 13754-13759[Abstract/Free Full Text]
55. Ottenhoff-Kalff, A., Rijksen, G., van, B. E., Hennipman, A., Michels, A., and Staal, G. (1992) Cancer Res. 52, 4773-4778[Abstract/Free Full Text]
56. Talamonti, M., Roh, M., Curley, S., and Gallick, G. (1993) J. Clin. Invest. 91, 53-60
57. Mao, W., Irby, R., Coppola, D., Fu, L., Wloch, M., Turner, J., Yu, H., Garcia, R., Jove, R., and Yeatman, T. (1997) Oncogene 15, 3083-3090[CrossRef][Medline] [Order article via Infotrieve]
58. Luttrell, D., Luttrell, L., and Parsons, S. (1988) Mol. Cell. Biol. 8, 497-501[Abstract/Free Full Text]
59. Wilson, L., Luttrell, D., Parsons, J., and Parsons, S. (1989) Mol. Cell. Biol. 9, 1536-1544[Abstract/Free Full Text]
60. Roche, S., Koegl, M., Barone, M. V., Roussel, M. F., and Courtneidge, S. A. (1995) Mol. Cell. Biol. 15, 1102-1109[Abstract]
61. Ralston, R., and Bishop, J. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 7845-7849[Abstract/Free Full Text]
62. Twamley, G., Kypta, R., Hall, B., and Courtneidge, S. (1992) Oncogene 7, 1893-1901[Medline] [Order article via Infotrieve]
63. Mori, S., Ronnstrand, L., Yokote, K., Engstrom, A., Courtneidge, S., Claesson-Welsh, L., and Heldin, C. (1993) EMBO J. 12, 2257-2264[Medline] [Order article via Infotrieve]
64. Zhan, X., Plourde, C., Hu, X., Friesel, R., and Maciag, T. (1994) J. Biol. Chem. 269, 20221-20224[Abstract/Free Full Text]
65. Landgren, E., Blume-Jensen, P., Courtneidge, S., and Claesson-Welsh, L. (1995) Oncogene 10, 2027-2035[Medline] [Order article via Infotrieve]
66. Maa, M., Wilson, L., Moyers, J., Vines, R., Parsons, J., and Parsons, S. (1992) Oncogene 7, 2429-2438[Medline] [Order article via Infotrieve]
67. Wu, H., Reynolds, A., Kanner, S., Vines, R., and Parsons, J. (1991) Mol. Cell. Biol. 11, 5113-5124[Abstract/Free Full Text]
68. Wu, H., and Parsons, J. (1993) J. Cell Biol. 120, 1417-1426[Abstract/Free Full Text]
69. Schaller, M., Borgman, C., Cobb, B., Vines, R., Reynolds, A., and Parsons, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196[Abstract/Free Full Text]
70. Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994) EMBO J. 13, 3748-3756[Medline] [Order article via Infotrieve]
71. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R., and Jove, R. (1998) Mol. Cell. Biol. 18, 2545-2552[Abstract/Free Full Text]
72. Garcia, R., Yu, C., Hudnall, A., Catlett, R., Nelson, K., Smithgall, T., Fujita, D., Ethier, S., and Jove, R. (1997) Cell Growth Differ. 8, 1267-1276[Abstract]
73. Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., and Jove, R. (1995) Science 269, 81-83[Abstract/Free Full Text]
74. Danial, N., Pernis, A., and Rothman, P. (1995) Science 269, 1875-1877[Abstract/Free Full Text]
75. Chin, H., Arai, A., Wakao, H., Kamiyama, R., Miyasaka, N., and Miura, O. (1998) Blood 91, 3734-3745[Abstract/Free Full Text]
76. Lund, T., Garcia, R., Medveczky, M., Jove, R., and Medveczky, P. (1997) J. Virol. 71, 6677-6682[Abstract]
77. Carlesso, N., Frank, D., and Griffin, J. (1996) J. Exp. Med. 183, 811-820[Abstract/Free Full Text]
78. Nelson, K., Rogers, J., Bowman, T., Jove, R., and Smithgall, T. (1998) J. Biol. Chem. 273, 7072-7077[Abstract/Free Full Text]
79. Weber-Nordt, R., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V., Mertelsmann, R., and Finke, J. (1996) Blood 88, 809-816[Abstract/Free Full Text]
80. Bromberg, J., Horvath, C., Besser, D., Lathem, W., and Darnell, J. J. (1998) Mol. Cell. Biol. 18, 2553-2558[Abstract/Free Full Text]
81. Campbell, G. S., Yu, C. L., Jove, R., and Carter-Su, C. (1997) J. Biol. Chem. 272, 2591-2594[Abstract/Free Full Text]
82. Chaturvedi, P., Reddy, M. V., and Reddy, E. P. (1998) Oncogene 16, 1749-1758[CrossRef][Medline] [Order article via Infotrieve]
83. Berlanga, J., Vara, J., Martin-Pérez, J., and Garcia-Ruiz, J. (1995) Mol. Endocrinol. 9, 1461-1467[Abstract/Free Full Text]
84. Erwin, R., Kirken, R., Malabarba, M., Farrar, W., and Rui, H. (1995) Endocrinology 136, 3512-3518[Abstract]
85. Clevenger, C., and Medaglia, M. (1994) Mol. Endocrinol. 8, 674-681[Abstract/Free Full Text]
86. Rosen, J. M., Zahnow, C., Kazansky, A., and Raught, B. (1998) Biochem. Soc. Symp. 63, 101-113[Medline] [Order article via Infotrieve]
87. Happ, B., Hynes, N. E., and Groner, B. (1993) Cell Growth Differ. 4, 9-15[Abstract]

Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
P. Barros, P. Jordan, and P. Matos
Rac1 Signaling Modulates BCL-6-Mediated Repression of Gene Transcription
Mol. Cell. Biol., August 1, 2009; 29(15): 4156 - 4166.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
E. M. Fox, T. M. Bernaciak, J. Wen, A. M. Weaver, M. A. Shupnik, and C. M. Silva
Signal Transducer and Activator of Transcription 5b, c-Src, and Epidermal Growth Factor Receptor Signaling Play Integral Roles in Estrogen-Stimulated Proliferation of Estrogen Receptor-Positive Breast Cancer Cells
Mol. Endocrinol., August 1, 2008; 22(8): 1781 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S.-H. Tan and M. T Nevalainen
Signal transducer and activator of transcription 5A/B in prostate and breast cancers
Endocr. Relat. Cancer, June 1, 2008; 15(2): 367 - 390.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. M. Mohankumar, J. K. Perry, N. Kannan, K. Kohno, P. D. Gluckman, B. S. Emerald, and P. E. Lobie
Transcriptional Activation of Signal Transducer and Activator of Transcription (STAT) 3 and STAT5B Partially Mediate Homeobox A1-Stimulated Oncogenic Transformation of the Immortalized Human Mammary Epithelial Cell
Endocrinology, May 1, 2008; 149(5): 2219 - 2229.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. Sakamoto, B. A. Creamer, A. A. Triplett, and K.-U. Wagner
The Janus Kinase 2 Is Required for Expression and Nuclear Accumulation of Cyclin D1 in Proliferating Mammary Epithelial Cells
Mol. Endocrinol., August 1, 2007; 21(8): 1877 - 1892.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. M. Weaver and C. M. Silva
Modulation of Signal Transducer and Activator of Transcription 5b Activity in Breast Cancer Cells by Mutation of Tyrosines within the Transactivation Domain
Mol. Endocrinol., October 1, 2006; 20(10): 2392 - 2405.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Fang, E. M. Kofoed, B. M. Little, X. Wang, R. J. M. Ross, S. J. Frank, V. Hwa, and R. G. Rosenfeld
A Mutant Signal Transducer and Activator of Transcription 5b, Associated with Growth Hormone Insensitivity and Insulin-Like Growth Factor-I Deficiency, Cannot Function as a Signal Transducer or Transcription Factor
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1526 - 1534.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
M. Shi, J. C. Cooper, and C.-L. Yu
A Constitutively Active Lck Kinase Promotes Cell Proliferation and Resistance to Apoptosis through Signal Transducer and Activator of Transcription 5b Activation
Mol. Cancer Res., January 1, 2006; 4(1): 39 - 45.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Y. Ma, G. M. Anderson, T. D. Gunn, V. Goffin, D. R. Grattan, and S. J. Bunn
Prolactin Specifically Activates Signal Transducer and Activator of Transcription 5b in Neuroendocrine Dopaminergic Neurons
Endocrinology, December 1, 2005; 146(12): 5112 - 5119.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. V. Clevenger
Roles and Regulation of Stat Family Transcription Factors in Human Breast Cancer
Am. J. Pathol., November 1, 2004; 165(5): 1449 - 1460.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Dong, D. L. Stenoien, J. Qiu, M. A. Mancini, and D. J. Tweardy
Reduced Intranuclear Mobility of APL Fusion Proteins Accompanies Their Mislocalization and Results in Sequestration and Decreased Mobility of Retinoid X Receptor {alpha}
Mol. Cell. Biol., May 15, 2004; 24(10): 4465 - 4475.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. V. Kazansky, D. M. Spencer, and N. M. Greenberg
Activation of Signal Transducer and Activator of Transcription 5 is Required for Progression of Autochthonous Prostate Cancer: Evidence from the Transgenic Adenocarcinoma of the Mouse Prostate System
Cancer Res., December 15, 2003; 63(24): 8757 - 8762.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. J. O'Toole, T. Inoue, L. Emerson, I. E. G. Morrison, A. R. Mackie, R. J. Cherry, and J. D. Norton
Id Proteins Negatively Regulate Basic Helix-Loop-Helix Transcription Factor Function by Disrupting Subnuclear Compartmentalization
J. Biol. Chem., November 14, 2003; 278(46): 45770 - 45776.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Xi, Q. Zhang, W. E. Gooding, T. E. Smithgall, and J. R. Grandis
Constitutive Activation of Stat5b Contributes to Carcinogenesis in Vivo
Cancer Res., October 15, 2003; 63(20): 6763 - 6771.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Xi, Q. Zhang, K. F. Dyer, E. C. Lerner, T. E. Smithgall, W. E. Gooding, J. Kamens, and J. R. Grandis
Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck
J. Biol. Chem., August 22, 2003; 278(34): 31574 - 31583.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
R.-A. Wang, R. K. Vadlamudi, R. Bagheri-Yarmand, I. Beuvink, N. E. Hynes, and R. Kumar
Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands
J. Cell Biol., May 12, 2003; 161(3): 583 - 592.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. B. Kabotyanski and J. M. Rosen
Signal Transduction Pathways Regulated by Prolactin and Src Result in Different Conformations of Activated Stat5b
J. Biol. Chem., May 2, 2003; 278(19): 17218 - 17227.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler
The Role of Prolactin in Mammary Carcinoma
Endocr. Rev., February 1, 2003; 24(1): 1 - 27.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. T. Kloth, K. K. Laughlin, J. S. Biscardi, J. L. Boerner, S. J. Parsons, and C. M. Silva
STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor
J. Biol. Chem., January 10, 2003; 278(3): 1671 - 1679.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. L. Grimm, T. N. Seagroves, E. B. Kabotyanski, R. C. Hovey, B. K. Vonderhaar, J. P. Lydon, K. Miyoshi, L. Hennighausen, C. J. Ormandy, A. V. Lee, et al.
Disruption of Steroid and Prolactin Receptor Patterning in the Mammary Gland Correlates with a Block in Lobuloalveolar Development
Mol. Endocrinol., December 1, 2002; 16(12): 2675 - 2691.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. D. Curlewis, S. P. Tam, P. Lau, D. H. L. Kusters, J. L. Barclay, S. T. Anderson, and M. J. Waters
A Prostaglandin F2{alpha} Analog Induces Suppressors of Cytokine Signaling-3 Expression in the Corpus Luteum of the Pregnant Rat: A Potential New Mechanism in Luteolysis
Endocrinology, October 1, 2002; 143(10): 3984 - 3993.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. T. Nevalainen, J. Xie, L. Bubendorf, K.-U. Wagner, and H. Rui
Basal Activation of Transcription Factor Signal Transducer and Activator of Transcription (Stat5) in Nonpregnant Mouse and Human Breast Epithelium
Mol. Endocrinol., May 1, 2002; 16(5): 1108 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Dong and D. J. Tweardy
Interactions of STAT5b-RARalpha , a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways
Blood, April 15, 2002; 99(8): 2637 - 2646.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Xie, M. J. LeBaron, M. T. Nevalainen, and H. Rui
Role of Tyrosine Kinase Jak2 in Prolactin-induced Differentiation and Growth of Mammary Epithelial Cells
J. Biol. Chem., April 12, 2002; 277(16): 14020 - 14030.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. L. Brockman, M. D. Schroeder, and L. A. Schuler
PRL Activates the Cyclin D1 Promoter Via the Jak2/Stat Pathway
Mol. Endocrinol., April 1, 2002; 16(4): 774 - 784.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Kirito, T. Watanabe, K.-i. Sawada, H. Endo, K. Ozawa, and N. Komatsu
Thrombopoietin Regulates Bcl-xL Gene Expression through Stat5 and Phosphatidylinositol 3-Kinase Activation Pathways
J. Biol. Chem., March 1, 2002; 277(10): 8329 - 8337.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. T. Kloth, A. D. Catling, and C. M. Silva
Novel Activation of STAT5b in Response to Epidermal Growth Factor
J. Biol. Chem., March 1, 2002; 277(10): 8693 - 8701.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. J. Ahonen, P. L. Harkonen, H. Rui, and M. T. Nevalainen
PRL Signal Transduction in the Epithelial Compartment of Rat Prostate Maintained as Long-Term Organ Cultures in Vitro
Endocrinology, January 1, 2002; 143(1): 228 - 238.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
E. Nijhuis, J.-W. J Lammers, L. Koenderman, and P. J. Coffer
Src kinases regulate PKB activation and modulate cytokine and chemoattractant-controlled neutrophil functioning
J. Leukoc. Biol., January 1, 2002; 71(1): 115 - 124.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
K. Miyoshi, J. M. Shillingford, G. H. Smith, S. L. Grimm, K.-U. Wagner, T. Oka, J. M. Rosen, G. W. Robinson, and L. Hennighausen
Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium
J. Cell Biol., November 12, 2001; 155(4): 531 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. Frasor, U. Barkai, L. Zhong, A. T. Fazleabas, and G. Gibori
PRL-Induced ER{alpha} Gene Expression Is Mediated by Janus Kinase 2 (Jak2) While Signal Transducer and Activator of Transcription 5b (Stat5b) Phosphorylation Involves Jak2 and a Second Tyrosine Kinase
Mol. Endocrinol., November 1, 2001; 15(11): 1941 - 1952.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
C V Clevenger and J B Kline
Prolactin receptor signal transduction
Lupus, October 1, 2001; 10(10): 706 - 718.
[Abstract] [PDF]

Home page
 Cell Growth Differ.Home page
A. V. Kazansky and J. M. Rosen
Signal Transducers and Activators of Transcription 5B Potentiates v-Src-mediated Transformation of NIH-3T3 Cells
Cell Growth Differ., January 1, 2001; 12(1): 1 - 7.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
K. Mowen and M. David
Regulation of STAT1 Nuclear Export by Jak1
Mol. Cell. Biol., October 1, 2000; 20(19): 7273 - 7281.
[Abstract] [Full Text]

Home page
 Cell Growth Differ.Home page
G. Chakravarty, D. Roy, M. Gonzales, J. Gay, A. Contreras, and J. M. Rosen
p190-B, a Rho-GTPase-activating Protein, Is Differentially Expressed in Terminal End Buds and Breast Cancer
Cell Growth Differ., July 1, 2000; 11(7): 343 - 354.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
G. Luo and L.-y. Yu-Lee
Stat5b Inhibits NF{kappa}B-Mediated Signaling
Mol. Endocrinol., January 1, 2000; 14(1): 114 - 123.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kazansky, A. V.
Right arrow Articles by Rosen, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kazansky, A. V.
Right arrow Articles by Rosen, J. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement